Smart Y C, Stewart J F, Bartlett L D, Brien J H, Forbes J F, Burton R C
Faculty of Medicine, University of Newcastle, N.S.W. Australia.
Breast Cancer Res Treat. 1990 Jul;16(1):23-8. doi: 10.1007/BF01806572.
An Enzyme Linked Immunosorbent Assay (ELISA) based on a monoclonal antibody, 3E1.2, was used to measure circulating Mammary Serum Antigen (MSA) in a study of 123 advanced breast cancer patients. Fifty two patients were monitored serially to investigate whether measurements of circulating MSA levels were of value in the management of advanced breast cancer patients on palliative therapy. Analysis of variance showed that circulating MSA levels at first presentation correlated with disease status both at initial presentation (p = 0.01) and also 4 months later (p = 0.003). At first presentation, the circulating MSA level also significantly correlated with the number of metastatic sites (p = 0.04), but this did not hold at 4 months. The circulating MSA levels did not at any time correlate with the type of treatment given nor age of the patient. We conclude that MSA might ultimately be useful in the management of advanced breast cancer patients as a prognostic marker for the course of the disease and for monitoring patient response to palliative hormonal therapy and chemotherapy.
在一项针对123例晚期乳腺癌患者的研究中，采用了基于单克隆抗体3E1.2的酶联免疫吸附测定（ELISA）来检测循环乳腺血清抗原（MSA）。对52例患者进行了连续监测，以研究循环MSA水平的检测在晚期乳腺癌姑息治疗患者管理中是否有价值。方差分析表明，首次就诊时的循环MSA水平与初次就诊时（p = 0.01）以及4个月后的疾病状态相关（p = 0.003）。首次就诊时，循环MSA水平也与转移部位数量显著相关（p = 0.04），但4个月时并非如此。循环MSA水平在任何时候都与所给予的治疗类型或患者年龄无关。我们得出结论，MSA最终可能对晚期乳腺癌患者的管理有用，可作为疾病进程的预后标志物以及监测患者对姑息性激素治疗和化疗的反应。
